Tropicetron in the treatment of schizophrenia

Tropisetron on negative symptoms in patients with chronic schizophrenia: a double blind and placebo controlled trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201106101556N24

Enrollment

Registered

2011-06-12

Start date

2011-07-06

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia. Schizophrenia, unspecified

Interventions

Intervention 1: Tablet Risperidone (6 mg/day) combined with 10mg/day of Tablets tropisetron as intervention group for 8 weeks. Intervention 2: Tablets Risperidone (6 mg/day) combined with Tablets plac

Treatment - Drugs

Placebo

Tablet Risperidone (6 mg/day) combined with 10mg/day of Tablets tropisetron as intervention group for 8 weeks

Tablets Risperidone (6 mg/day) combined with Tablets placebo as control group for 8 weeks

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Age between 18-50,2-Diagnosis of Schizophrenia based on DSM IV 3-chronic Schizophrenia, 4- minimum Score of 20 on negative subscale of PANSS,5-stable on antipsychotic Exclusion Criteria:1- Substance dependence,2- IQ <70,3-any other mental disorder on axis I, 4-Any serious medical or neurological problem ,5- receiving oral antipsychotic medications during the last week or receiving any depot antipsychotic medication during the last month,6- receiving ECT during the last 14 days

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of schizophrenia. Timepoint: Baseline and weeks 2-4-6-8 after beginig of treatment. Method of measurement: Positive and Negative Syndrome Scale (PANSS).	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026